Page last updated: 2024-12-09

2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide is a chemical compound with the molecular formula C14H16N4O3. It's a complex molecule with a specific structure, but you're probably interested in its potential biological properties, as it's commonly encountered in research.

**Let's break down the importance of this compound in research:**

* **Potential Biological Activity:** This compound is often synthesized and studied in research laboratories due to its potential biological activity. Its structure suggests it might possess properties that interact with biological systems, like acting as:
* **An antifungal agent:** The triazole ring (1H-1,2,4-triazol-5-yl) is a common motif in antifungal drugs.
* **An anti-inflammatory agent:** The phenoxy group (4-ethylphenoxy) might contribute to anti-inflammatory activity.
* **A pesticide:** The compound's structure resembles known pesticide molecules.
* **A drug candidate:** It could act as a starting point for developing new drugs for various diseases.

* **Research Focus:** Research involving this compound typically focuses on understanding:
* **Its mechanism of action:** How does it interact with biological targets (like enzymes, proteins, or cell membranes)?
* **Its efficacy:** Does it achieve the desired biological effect (e.g., killing fungi, reducing inflammation)?
* **Its safety profile:** Is it toxic to humans or the environment?

**Importance of Research:** This research is crucial for:
* **Developing new treatments for fungal infections:** Fungal infections are a growing health concern worldwide.
* **Finding better ways to control inflammation:** Inflammation plays a role in numerous diseases.
* **Designing safer and more effective pesticides:** Pesticides are essential for agriculture, but their environmental impact is a concern.
* **Discovering new drug candidates:** This compound might lead to the development of novel therapies for a range of medical conditions.

**Note:** Research is still ongoing for this specific compound. There may not be any conclusive evidence yet about its exact biological activity or its effectiveness as a drug candidate.

**Further Research:** To find out more about the specific research on 2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide, you'd need to consult scientific databases like PubMed or Google Scholar using relevant keywords.

Cross-References

ID SourceID
PubMed CID698942
CHEMBL ID1373057
CHEBI ID92064

Synonyms (22)

Synonym
2-(4-ethylphenoxy)-n-4h-1,2,4-triazol-3-ylacetamide
smr000291670
MLS000684020
TIMTEC1_001816
OPREA1_117681
OPREA1_665440
MLS-0265844.0001 ,
HMS1539C12
BRD-K03704870-001-01-4
MLS002460489
2-(4-ethylphenoxy)-n-(1h-1,2,4-triazol-5-yl)acetamide
AKOS001673076
HMS2228I20
HMS3355F07
cid_698942
2-(4-ethylphenoxy)-n-(1h-1,2,4-triazol-5-yl)ethanamide
bdbm51412
CHEMBL1373057
SR-01000495481-1
sr-01000495481
CHEBI:92064
Q27163859
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency13.45910.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency56.23410.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency14.89200.004110.890331.5287AID504466; AID504467
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency19.95260.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency44.66840.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.16230.01262.451825.0177AID485313
pyruvate kinase PKM isoform aHomo sapiens (human)Potency8.91250.04017.459031.6228AID1631; AID1634
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency4.46680.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.89130.00798.23321,122.0200AID2546
survival motor neuron protein isoform dHomo sapiens (human)Potency17.78280.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproproteinHomo sapiens (human)EC50 (µMol)4.17000.227025.090486.8000AID1659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]